Lista de obras - Gerard Sanacora - Dominio Público Uruguay

1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism ⬇️

artículo científico publicado el 9 de diciembre de 2011

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

artículo científico publicado en 2017

A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder

artículo científico publicado en 2015

Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice ⬇️

artículo científico publicado el 21 de julio de 2011

Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder

artículo científico publicado en 2011

Beyond monoamines: glutamatergic function in mood disorders

artículo científico publicado en 2005

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

artículo científico publicado en 2012

Cell-type specific modulation of NMDA receptors triggers antidepressant actions

artículo científico publicado en 2020

Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus

artículo científico publicado en 2008

Clinical studies implementing glutamate neurotransmission in mood disorders

artículo científico publicado en 2003

Cortical GABA Levels in Primary Insomnia ⬇️

artículo científico publicado el 1 de junio de 2012

Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.

artículo científico publicado en 2014

Delayed Amnesic Syndrome after Riluzole Use in Major Depressive Disorder: A Case Report ⬇️

artículo científico publicado el 6 de marzo de 2013

Effects of ketamine in treatment-refractory obsessive-compulsive disorder

artículo científico publicado en 2012

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression

artículo científico publicado en 2006

From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders

artículo científico publicado en 2013

GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action

artículo científico publicado en 2007

Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression

artículo científico publicado en 2002

Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

artículo científico publicado en 2014

Glutamate metabolism in major depressive disorder

artículo científico publicado en 2014

In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.

artículo científico publicado en 2014

Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla.

artículo científico publicado en 2011

It is time to take a stand for medical research and against terrorism targeting medical scientists

artículo científico publicado en 2008

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics

artículo científico publicado en 2014

Ketamine: A Paradigm Shift for Depression Research and Treatment

scientific article published on 01 March 2019

Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial

artículo científico publicado en 2010

Major depression: emerging therapeutics

artículo científico publicado en 2008

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin

artículo científico publicado en 2020

Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia

artículo científico publicado en 2009

New understanding of mechanisms of action of bipolar medications

artículo científico publicado en 2008

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms

scientific article published on 04 December 2006

Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting

artículo científico publicado en 2012

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond

artículo científico publicado en 2013

Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies

artículo científico publicado en 2009

Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction

artículo científico publicado en 2015

Reviewing medications for bipolar disorder: understanding the mechanisms of action.

artículo científico publicado en 2009

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial ⬇️

artículo científico publicado en 2015

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

artículo científico publicado en 2005

Riluzole in the treatment of mood and anxiety disorders

scientific article published on January 2008

Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.

artículo científico publicado en 2013

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

artículo científico publicado en 2008

Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy

artículo científico publicado en 2005

Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.

artículo científico publicado en 2017

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

artículo científico publicado en 2016

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

scientific article published on May 2008

The NMDA receptor as a therapeutic target in major depressive disorder

artículo científico publicado en 2007

The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS ⬇️

artículo científico publicado el 12 de enero de 2011

The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

scientific article published on 25 May 2018

The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission

artículo científico publicado en 2011

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders

artículo científico publicado en 2012

Lista de obras de Gerard Sanacora

1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism ⬇️

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

A history of early life parental loss or separation is associated with successful cognitive-behavioral therapy in major depressive disorder

Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice ⬇️

Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder

Beyond monoamines: glutamatergic function in mood disorders

Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients.

Cell-type specific modulation of NMDA receptors triggers antidepressant actions

Chronic riluzole treatment increases glucose metabolism in rat prefrontal cortex and hippocampus

Clinical studies implementing glutamate neurotransmission in mood disorders

Cortical GABA Levels in Primary Insomnia ⬇️

Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.

Delayed Amnesic Syndrome after Riluzole Use in Major Depressive Disorder: A Case Report ⬇️

Effects of ketamine in treatment-refractory obsessive-compulsive disorder

Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression

From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders

GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action

Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression

Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Glutamate metabolism in major depressive disorder

In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.

Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla.

It is time to take a stand for medical research and against terrorism targeting medical scientists

Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics

Ketamine: A Paradigm Shift for Depression Research and Treatment

Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial

Major depression: emerging therapeutics

Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin

Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia

New understanding of mechanisms of action of bipolar medications

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms

Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond

Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies

Regulation of extrasynaptic glutamate levels as a pathophysiological mechanism in disorders of motivation and addiction

Reviewing medications for bipolar disorder: understanding the mechanisms of action.

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial ⬇️

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

Riluzole in the treatment of mood and anxiety disorders

Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy

Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

The NMDA receptor as a therapeutic target in major depressive disorder

The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS ⬇️

The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?

The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders